License and Collaboration Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 9 Months Ended 12 Months Ended
Oct. 28, 2016
Dec. 31, 2014
Oct. 31, 2014
Aug. 31, 2012
Dec. 31, 2011
Jul. 31, 2009
Feb. 28, 1997
Sep. 30, 2016
Jan. 31, 2012
Jan. 31, 2010
Sep. 30, 2014
Sep. 30, 2013
Aug. 31, 2009
Royalty Sharing Agreement [Member] | Subsequent Event [Member] | Transcept Pharmaceuticals, Inc. [Member]                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Percentage of royalty income paid for payment obligation 50.00%                        
Allergan [Member]                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Aggregated amount payable future regulatory milestones               $ 17,000,000          
Milestone payments on acceptance of an NDA submission               5,000,000          
Allergan [Member] | Crl Agreement [Member]                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Fees earned                   $ 4,000,000      
Allergan [Member] | New Drug Application [Member]                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Fees earned                   $ 1,000,000      
Allergan [Member] | Crl Agreement Phase 2 Trials [Member]                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Fees earned                 $ 2,500,000        
Allergan [Member] | Crl Agreement Phase 3 Trials [Member]                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Fees earned   $ 4,000,000                      
Tufts [Member]                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Shares issued             1,024            
Milestone payments, maximum               300,000          
Milestone payments, paid               50,000          
Royalty, payable               $ 25,000          
Purdue Pharma [Member]                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Non-refundable license fees                         $ 25,000,000
Range of company tier base royalties on net sales of Intermezzo               From the mid-teens up to the mid-20% level          
Validity of collaboration agreement           15 years              
Advance notice to terminate collaboration agreement               180 days          
Rate of royalty receivable     100.00%                    
Cash proceeds from sale or disposition of intermezzo     90.00%                    
Purdue Pharma [Member] | Maximum [Member]                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Amount receivable on achievement of net sales criteria               $ 70,000,000          
Purdue Pharma [Member] | Intellectual Property [Member]                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Non-refundable milestone payments made       $ 10,000,000 $ 10,000,000                
SNBL [Member]                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Non refundable license fee                       $ 1,000,000  
Aggregate amount obligated for achievement of certain development                       $ 41,500,000  
SNBL [Member] | Maximum [Member]                          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                          
Amount receivable on achievement of net sales criteria                     $ 2,000,000